BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008;9:839-49. [PMID: 18345959 DOI: 10.1517/14656566.9.5.839] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Ikenoue T, Naito H, Kitamura T, Hattori H. Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report. J Med Case Rep 2017;11:296. [PMID: 29047386 DOI: 10.1186/s13256-017-1468-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
2 Joré C, Brun JF, Varlet-Marie E. Rise in RBC aggregability and concomitant decrease in blood pressure 10 days after injection of the long acting erythropoietin analogue methoxy polyethylene glycol-epoetin-β (MIRCERA®). Clin Hemorheol Microcirc 2016;64:809-16. [PMID: 27767968 DOI: 10.3233/CH-168015] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Liu WS, Chan HL, Lai YT, Yang YH, Teng HW, Liu CK, Li SY, Yang CY, Liu TY, Lin CC. Shift from darbepoetin-α to continuous erythropoietin receptor activator decreases serum aluminium concentration in patients on hemodialysis. Environ Toxicol Pharmacol 2016;45:108-14. [PMID: 27267426 DOI: 10.1016/j.etap.2016.05.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Murua A, Orive G, Hernández RM, Pedraz JL. Emerging technologies in the delivery of erythropoietin for therapeutics. Med Res Rev 2011;31:284-309. [PMID: 19967731 DOI: 10.1002/med.20184] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
5 Kihara M, Matsuo-Tezuka Y, Noguchi-Sasaki M, Yorozu K, Kurasawa M, Shimonaka Y, Hirata M. Visualization of 57Fe-Labeled Heme Isotopic Fine Structure and Localization of Regions of Erythroblast Maturation in Mouse Spleen by MALDI FTICR-MS Imaging. J Am Soc Mass Spectrom 2017;28:2469-75. [PMID: 28819889 DOI: 10.1007/s13361-017-1768-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 2008;10:e36. [PMID: 19040789 DOI: 10.1017/S1462399408000860] [Cited by in Crossref: 77] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
7 Oak CY, Kim NH. Anemia and nutrition in end stage renal disease patient. J Korean Med Assoc 2013;56:592. [DOI: 10.5124/jkma.2013.56.7.592] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Bishara N, Ohls RK. Current Controversies in the Management of the Anemia of Prematurity. Seminars in Perinatology 2009;33:29-34. [DOI: 10.1053/j.semperi.2008.10.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
9 Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe LM, Labourey JL, Lepille D, Maloisel F, Mouysset JL, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H; ORHEO study group. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study. BMC Cancer 2014;14:503. [PMID: 25011615 DOI: 10.1186/1471-2407-14-503] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
10 Sathyanarayana P, Houde E, Marshall D, Volk A, Makropoulos D, Emerson C, Pradeep A, Bugelski PJ, Wojchowski DM. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood 2009;113:4955-62. [PMID: 19264917 DOI: 10.1182/blood-2008-08-172320] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
11 Reihlen P, Blobel M, Weiß P, Harth J, Wittmann J, Leenders F, Thevis M. Introduction of a PEGylated EPO conjugate as internal standard for EPO analysis in doping controls. Drug Test Anal 2021. [PMID: 34905300 DOI: 10.1002/dta.3211] [Reference Citation Analysis]
12 Timms M, Steel R, Vine J. Identification of recombinant human EPO variants in greyhound plasma and urine by ELISA, LC-MS/MS and western blotting: a comparative study: EPO testing in greyhounds by ELISA, LC-MS/MS and western blotting. Drug Test Analysis 2016;8:164-76. [DOI: 10.1002/dta.1835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wojchowski DM, Sathyanarayana P, Dev A. Erythropoietin receptor response circuits. Curr Opin Hematol 2010;17:169-76. [PMID: 20173635 DOI: 10.1097/MOH.0b013e328338008b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 0.6] [Reference Citation Analysis]
14 Magwood JS, Lebby A, Chen B, Kessler S, Norris L, Bennett CL. Emerging drugs for treatment of anemia of chronic kidney disease. Expert Opinion on Emerging Drugs 2013;18:421-9. [DOI: 10.1517/14728214.2013.836490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Duntas LH, Popovic V. Hormones as doping in sports. Endocrine 2013;43:303-13. [DOI: 10.1007/s12020-012-9794-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
16 Aizawa K, Kawasaki R, Tashiro Y, Hirata M, Endo K, Shimonaka Y. Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase. Int J Hematol 2016;104:182-9. [DOI: 10.1007/s12185-016-2000-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Kessler M, Landais P, Bataille P, Yver L, Koné S, Kraemer S, Brillet G, Canivet E. [Anemia management in French hemodialysis patients: DiaNE study results at 3 years (DiaNE2)]. Nephrol Ther 2011;7:182-7. [PMID: 21227765 DOI: 10.1016/j.nephro.2010.11.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Liu WS, Chu DC, Chan HL, Li SY, Liu CK, Yang CY, Chen YW, Lee PC, Lai YT, Lin CC. Fixed dose of long-acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis. Clin Exp Pharmacol Physiol 2016;43:875-82. [PMID: 27385380 DOI: 10.1111/1440-1681.12618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Lawrence PB, Gavrilov Y, Matthews SS, Langlois MI, Shental-bechor D, Greenblatt HM, Pandey BK, Smith MS, Paxman R, Torgerson CD, Merrell JP, Ritz CC, Prigozhin MB, Levy Y, Price JL. Criteria for Selecting PEGylation Sites on Proteins for Higher Thermodynamic and Proteolytic Stability. J Am Chem Soc 2014;136:17547-60. [DOI: 10.1021/ja5095183] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
20 Liu WS, Wu YL, Li SY, Yang WC, Chen TW, Lin CC. The waveform fluctuation and the clinical factors of the initial and sustained erythropoietic response to continuous erythropoietin receptor activator in hemodialysis patients. ScientificWorldJournal 2012;2012:157437. [PMID: 22619601 DOI: 10.1100/2012/157437] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
21 Alsalimy N, Awaisu A. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. Int J Clin Pharm 2014;36:1115-25. [DOI: 10.1007/s11096-014-0023-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
22 Frimat L, Mariat C, Landais P, Koné S, Commenges B, Choukroun G. Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis. BMJ Open 2013;3:e001888. [PMID: 23474787 DOI: 10.1136/bmjopen-2012-001888] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
23 John MJ, Jaison V, Jain K, Kakkar N, Jacob JJ. Erythropoietin use and abuse. Indian J Endocrinol Metab. 2012;16:220-227. [PMID: 22470858 DOI: 10.4103/2230-8210.93739] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
24 Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009;14:363-80. [PMID: 19453284 DOI: 10.1517/14728210902907847] [Cited by in Crossref: 188] [Cited by in F6Publishing: 166] [Article Influence: 14.5] [Reference Citation Analysis]
25 Winkler J. Therapeutic oligonucleotides with polyethylene glycol modifications. Future Med Chem 2015;7:1721-31. [PMID: 26465713 DOI: 10.4155/fmc.15.94] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]